{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Sensory Changes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Motor Changes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Jaw Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Laryngeal Nerve Dysfunction"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"description":"Types of neurotoxicities reported. Each patient was only counted once for each type of neurotoxicity, but a patient could be counted in more than 1 type of neurotoxicity. For example, if a patient experienced constipation 3 times, they are included once for constipation. If a patient experienced sensory changes and motor changes, they are included once for sensory changes and once for motor changes.","groups":[{"description":"Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).","id":"OG000","title":"Arm I Glutamic Acid"},{"description":"Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).","id":"OG001","title":"Arm II Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who returned a post baseline Neurotox Questionnaire","reportingStatus":"POSTED","timeFrame":"10 Weeks","title":"Types of Neurotoxicities","type":"SECONDARY","unitOfMeasure":"Participants"}